Neurologix, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1999-01-01
- Employees
- 12
- Market Cap
- -
- Website
- http://www.neurologix.net
Clinical Trials
3
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Long Term Follow-Up Study for rAAV-GAD Treated Subjects
Terminated
- Conditions
- Parkinson's Disease
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Neurologix, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT01301573
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Study of AAV-GAD Gene Transfer Into the Subthalamic Nucleus for Parkinson's Disease
Phase 2
Terminated
- Conditions
- Parkinson's Disease
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2012-02-22
- Lead Sponsor
- Neurologix, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT00643890
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Safety Study of Subthalamic Nucleus Gene Therapy for Parkinson's Disease
Phase 1
Completed
- Conditions
- Parkinson's Disease
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Neurologix, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00195143
- Locations
- 🇺🇸
North Shore University Hospital, Manhasset, New York, United States
News
No news found